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MOLECULAR MECHANISM OF XY GONADAL
DYSGENESIS
Griendy Indig-Weingarten
One of the fundamentals of human sociology is the characterization of the
people around us based on gender. We tend to think of gender as a strict binary
system where the option is clear: boy or girl. Although society usually honors this
dichotomy, biology allows more flexibility to the definition of male versus female.
Estimates state that one in every 2000 births is one with a disorder of sex development
(The Intersex Society of North America 2006). Some of the disorders are visually
obvious while others are only discovered later on in life. Regardless of when the
disease first becomes obvious, all of these disorders constitute a variation along the
standard development of a male or female. Therefore, to understand disorders of sex
development, one must first understand what constitutes normal sex development. As
in all of embryology, development is controlled by many different genetic codes and
the pathways they encode. Therefore, variation along any gene responsible for any
part of the sex differentiation mechanism will result in a deviation from the expected.

NORMAL SEX DEVELOPMENT
The identity of the sperm that successfully penetrates the ovum is the official
beginning of sex determination. When meiosis of the spermatocyte is completed, the
mature haploid spermatozoa can either have an X or a Y as its twenty-third
chromosome. When this particular sperm penetrates the ovum, the identity of its
twenty-third chromosome determines the genetic sex. This is the first step of sex
determination. Further sex development is divided into two parts: primary sex
determination and secondary sex determination. Primary determination involves the
development of the fetus’s gonads. Once formed, the gonads start producing hormones
which initiate secondary sex development. Secondary sex development includes the
development of duct systems and external genitalia. Secondary sex development is
only complete after puberty (Gilbert 2010).

PRIMARY SEX DIFFERENTIATION

Regardless of their karyotype, initially all embryos present a common set of
genital structures. These include the gonads, the internal duct system, and the external
genitalia. The development of the genital system begins at the fourth week of
embryonic life. The entire genital system is derived from the intermediate mesoderm
and urogenital sinus except for the gametes which emigrate from the mesoderm of the
yolk sack. The intermediate mesoderm differentiates to form the adrenal cortex and
the start of the urogenital ridge originating as the nephrogenic cord. The urogenital
ridge is the site of the development of the urinary and reproductive system. The
cephalic portion of the nephrogenic cord further matures to form the pronephros,
which is mostly an embryonic structure. The more caudal portions of the nephrogenic
cord form the mesonephros and the pronephric duct which later forms the
mesonephric duct. The genital ridge arises along the middle portion of the
mesonephros. This is the central location for the development of the gonadal and
genital structures. The caudal (posterior) portion of mesonephric duct fuses with
mesonephric tubules and continues to extend and connect to the urogenital sinus.
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Then the most caudal
area of the nephrogenic
ridge further develops
into the metanephros
which is the permanent
kidney
(Figure
1)
(McMahon et al. 2008).

GONADS

The gonads are Figure 1: Nephrogenic Cord.
unique
embryonic Source: http://vanat.cvm.umn.edu/TFFlectPDFs/LectEmbUrinarySys.pdf.
structures because they
are the only bipotential organs. They can develop into ovaries or testes. Gonads
usually appear at week four but remain undifferentiated until week seven. At about 3-4
weeks, the mesonephros is at its largest size, and it is at this point that the epithelial
layer of the mesonephros, also known as the coelomic epithelium, starts to proliferate
into the surrounding mesenchyme, or undifferentiated loose connective tissue, and
form the primary sex cords. These cords will surround the entering germ cell to form
the gonadal cord. At this point, the gonadal tissue will start to differentiate to testes or
ovaries.

MALE GONADAL DEVELOPMENT
An XY fetus, at around the eighth week, will start developing testicular tissue.
This begins with the differentiation of the gonadal cord into the Sertoli supporting
cells. These cells form processes that surround the primordial germ cells and
eventually mature into Sertoli cells. At the same time, cells migrating from the
mesonephros, called peritubular myoid cells, form a single layer around the gonadal
cords. These peritubuluar myoid cells contribute to the structural integrity of the testis
cord and will support spermatogenesis later in the adult male’s life (Buehr et al. 1993).
It is at this point (around the eight week) that the gonadal cord is recognizable as the
first form of the testis cord. The testis cord then comes in contact with the mesonephric
tubules which are connected to the mesonephric duct, causing a capsule called the
tunica albuginea to form around the testes. Meanwhile, the testis cords continue to
create a dense network called the rete testis. The rete testis functions later on as the
carrier of sperm from the seminiferous tubules out of the testicles through the efferent
duct which was derived from the mesonephric tubules. At 20 weeks, the testis cord
forms the straight and convoluted seminiferous tubules. The straight tubules are
connected to the rete testis and do not have any germ cells within them. The
convoluted tubules are a continuation of the seminiferous tubules and contain the
primordial germ cells. Spermatogenesis takes place in the convoluted tubules (Celio et
al. 1999). Once the testis is formed, some primordial germ cells differentiate into a presperm state called T1-prospermatogonia and remain that way until puberty (Gilbert
2010).
Another important part of testicular development is the differentiation of the
Leydig cells. These cells originate from mesenchyme, or the undifferentiated loose
connective tissue in between the testis cords. These Leydig cells eventually produce
testosterone which will be crucial to further male differentiation. Because of its steroid
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producing nature, Leydig cells tend to cluster near the testicular vasculature (Wilhelm
2007).

FEMALE GONADAL DEVELOPMENT
In the case of an XX embryo, the gonads usually develop into ovaries. The
ovaries start developing during the eight week. In the absence of testis determining
genes, the genital ridge will differentiate into ovaries. However, unlike testis, in which
the testis cord forms early on in embryogenesis, the functional unit of the female
gonads—the ovarian follicles—completely mature only at puberty. During fetal
development, primordial follicles are formed. These follicles are usually formed
around 16-24 weeks after fertilization (Celio et al. 1999). The ovarian development
begins with the migration of the primordial germ cells into the genital ridge and the
gonadal cord partially atrophies. Later on, the primordial germ cells proliferate and
form the primordial oocyte, or the oogonium. At around the fifth month, the oogonia
are arrested at prophase of the first meiosis and are subsequently surrounded by
pregranulosa cells which differentiated from the gonadal cord. These granulosa cells
are connected with cellular bridges and high levels of vasculature. One of the key
differences between the male and female primordial germ cells is that while all the male
cells will continue to proliferate and mature to sperm from the age of puberty
throughout a lengthy adult life, only the female cells that have matured and were
arrested at prophase of the first meiotic division in utero will mature into ooctyes.

MOLECULAR GENETICS OF GONAD DEVELOPMENT
TESTIS PATHWAY

Genetic sex is defined as the presence of an XX or XY karyotype. In either
case, one X will be inactivated, allowing the X or the Y to be the defining chromosome
in sex determination. The Y chromosome carries a dominant testis-determining gene
which actively promotes testicular development. Absence of the gene, regardless of the
identity of the rest of the chromosome, will cause the embryo to go into “default”
development and continue to develop as a female. It is for this reason that sex
determination is sometimes equated with testis determination. This was proven by
Alfred Jost when he castrated rabbits in utero and the rabbits’ development continued
according to the female pattern (Jost 1972). Later research showed the testisdetermining gene to be the SRY gene on the short arm of the Y chromosome. In fact,
the research that discovered the connection between the SRY gene and testis
determination was carried out on XY females and Turner Syndrome patients (Berta et
al. 1990).
SRY: SEX- DETERMINING REGION Y
The SRY gene is located on the upper short arm of the Y chromosome. In
studies using XX reversed males and XY reversed females, results showed that a fetus
with the Y short arm, even when missing the long Y arm, would develop testis.
Accordingly, any individual missing the Y short arm would not develop testis.
Additionally, if the SRY gene is inserted in the genome of a normal XX mouse, the XX
mouse would develop testis (Koopman et al. 1991). The SRY gene is expressed in the
bipotential gonads immediately before differentiation of the Sertoli cells begins, at
around eight weeks, and is deactivated a few days later (Cotinot et al. 2002). Although
SRY is deactivated after a short window, while active, it synthesizes the SRY
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transcription factor whose primary role is to activate the SOX9 gene, allowing
differentiation to continue even after SRY is deactivated.
SOX9
The SOX9 gene is located on the seventeenth chromosome. SOX genes are
called transcription factors due to their nature of transcribing proteins that can bind to
specific locations on DNA to control gene activity. SOX9 is involved in many
developmental processes, particularly skeletal formation. In fact, the role of SOX9 in
testis formation was discovered when a link between SOX9 and a condition called
campomelic dysplasia was discovered. Campomelic dysplasia patients exhibit multiple
skeletal abnormalities. Interestingly enough, however, 75% of the 46 XY patients with
campomelic dysplasia were sex-reversed females (Cooke et al. 1985). This led
researchers to discover that when SOX9 is activated in the genital ridge, it induces
testis formation. Studies have shown that mice missing the SRY gene but possessing an
extra copy of the SOX9 will develop as male. Accordingly, mammals possessing the
SRY gene but lacking the SOX9 gene will not develop male (Huang et al. 1999).
SOX9 works in several different manners:
• It activates its own promoter, creating a positive feedback loop which allows it
to be active for a longer period of time (Sekido and Lovell-Badge 2008).
• It blocks genes that are involved in ovary formation (de Santa Barbara et al.
2000).
• It can bind and activate different genes necessary for testicular development.
• It promotes the gene expression necessary to produce fibroblast growth factors
that are critical for Sertoli Cells precursors.
• It binds to the gene that promotes the production of anti-mullerian factor (de
Santa Barbara et al. 2000).
SOX9 is detected in
In the cytoplasm, SRY is bound by
the somatic cells in the
calmodulin (CaM) and importin &
(Imp&), which recognize the N- and
human fetal gonads as early
C-terminal nuclear localization
as the sixth week. When the
signals (NLSs) on SRY, respectively,
Sertoli
cells
start
and recruit it to enter the nucleus. At
differentiating, SOX9 is
10.5 dpc, SRY and steroidogenic
expressed in the nuclei of
factor 1 (SF1) bind directly to
specific sites (`TESCO', testisthe cells (de Santa Barbara
specific enhancer of Sox9 core) that
et al. 2000). Studies done
lie within the gonadal specific
on SOX9 have found that it
enhancer of Sox9 (indicated by the
very often works together
coloured regions on the DNA) and
with a nuclear receptor
upregulate Sox9 expression
cooperatively. At 11.5 dpc, after
called steroidogenic factor-1
initiation of Sox9 expression, an auto(SF-1) which is activated
regulation system operates in which
by the NR5A1 gene. The
SOX9 also binds directly to TESCO
relationship between the
with SF1 to prolong and amplify Sox9
SRY, SOX9, and SF1 is
expression. Abbreviations: SOX9,
explained in Figure 2.
SRY box containing gene 9; SRY,
sex-determining region on the
NR5A1
chromosome Y.
NR5A1 is sometimes
Figure 2: Cellular mechanism of SRY function. Source:
referred to as the SF-1 gene http://dev.biologists.org/content/137/23/3921.full
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because it encoded the SF-1 receptor. The NR5A1 gene spans seven exons and is
located on the ninth chromosome (Johns Hopkins University School of Medicine
2011). It functions in gonadal differentiation and in steriodogenesis. Knockout mice
(mice that were genetically altered) missing the NR5A1 gene developed with complete
adrenal and gonadal agenesis. Studies show that SF-1 is involved early in
embryogenesis during development of the bipotential gonad. Although it is not
completely understood how SF-1 functions in the embryogenetic stage, mice missing
the part of the NR5A1 gene that encodes for SF-1 never developed a genital ridge. SF-1
is already active in humans at four weeks when the gonadal ridge starts to form, and its
levels remain high in the testis even once the SRY shuts off. SF-1 aids in activating
SOX9 and continues to work with SOX9 to elevate the anti-mullerian hormone
transcription. As the name steriodogenic indicates, SF-1 is involved in hormone
production. It is involved in multiple steroid-producing functions, such as
collaborating with SOX9 to produce AMH (anti-mullerian hormone), and activating
genes involved with testosterone production in Leydig cells (Shen et al. 1994). Mice
lacking the SF-1 gene lack both adrenal glands and gonads, proving that the SF-1 gene
is involved in early embryogenesis of the urinary and reproductive system (Luo et al.
1994).

OVARY PATHWAY
In order to provide a complete picture of development, the molecular pathway
of the ovaries is briefly discussed, although these genes are not involved in XY
Gonadal Dysgenesis.
WNT4
Early on, WNT4 is expressed in the genital ridge in both male and female
embryos. However, its expression, while still maintained in the fetal ovaries, is
undetectable in the fetal testes. Mice that lack the gene will fail to develop ovaries
(Cotinot et al. 2002).
R-SPONDIN-1
Another critical gene is R-spondin-1, a protein expressed by RSPO1. An XX
fetus with gene mutation in RSP01 will be XX male. RSPO1 acts together with WNT4
to produce beta-catenin, which activates further ovarian development, and block SOX9
production. An XY fetus with a duplication of the WNT4 and RSPO1 on its
chromosome will develop ovaries instead of testis (Gilbert 2010).
(There are many other genes involved in both testis development and ovarian
development that are not discussed in this paper.)

SECONDARY SEX DEVELOPMENT

Once the gonads are formed, they start to produce hormones. These hormones
are initiators of secondary sex development. Once these hormones begin to be
secreted, secondary sex development can start. It is important to note that primary and
secondary developments do overlap, as the testes and ovaries continue to develop once
steroids are produced.
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INTERNAL DUCT SYSTEM
The gonads are just one part of the
sex differentiation process. The ducts
system, like the gonads, start out in an
undifferentiated
state.
In
the
undifferentiated stage, the embryo presents
with mesonephric ducts, also known as the
Wolffian ducts. Paramesonephronic ducts,
which appear in the sixth week, form part
of the urogenital cord. The Wolffian ducts
form from the nephrogenic cord and
Figure 3: Internal Duct System
develop toward the cloaca. Mesonephric 1-Mesonephros
tubules, another part of the mesonephros 2-Paramesonephric Duct
involved in the development of the internal 3-Mesonephric Duct
ducts, arise from the mesenchyme of the 4-Indiffernt Gonads
mesonephros and eventually fuse with the 5-Urogenital Sinus
Source: Celio et al. 1999.
mesonephric duct to create a passage to the
cloaca (Schoenwolf et al. 2009). The Mullerian Duct is formed when the coelomic
epithelium, near the top of the mesonephros, invaginates. Both the Mullerian and the
Wolffian ducts continue to grow caudally towards the urogenital sinus (Figure 3)
(Sweeney 1998 ).

MALE DUCT SYSTEM DEVELOPMENT

During early embryogenesis, the Wolffian duct serves as an excreting duct for
the mesonephros. Once the metanephros becomes functional, most of the mesonephric
duct atrophies, and the part that remains is dependent on the testosterone released
from the Leydig cells in the fetal testis. In the eighth week of gestation, the Leydig cells
start releasing testosterone and thus begin two important aspects of the internal male
duct system development. One is the atrophying of the paramesonephric duct, and the
other is the further development of the mesonephric duct (Celio et al. 1999). The
undifferentiated state includes both sets of ducts, and with the start of duct
differentiation, the paramesonephric duct starts to atrophy due to the effect of antimullerian hormone released by the Sertoli cells within the seminiferous tubules. It is
interesting to note that a small part of the paramesonephric duct does remain and
differentiates into the appendix testis (Jacob and Barteczko 2005). Meanwhile, the
Leydig cells begin releasing testosterone to support the development of the
mesonephric duct. Most of the top portion of the Wolffian duct atrophies, leaving only
the portion which differentiates into the efferent duct, epididymis, vas deferens, and
seminal vesicles.

FEMALE DUCT SYSTEM DEVELOPMENTS

In a human embryo, the absence of the anti-mullerian hormone causes the
undifferentiated ducts to develop into the female duct system. The mesonephric ducts
and tubules atrophy, and the paramesonephric duct further develops. In the eighth
week, the two lower portions of the mullerian duct fuse. This fused portion is the site
of the uterus. The upper portion of the paramesonephric duct proliferates outwards
towards the gonad and develops as the fallopian tubes. The lowest portion forms the
utero-vaginal canal (Celio et al. 1999).
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EXTERNAL GENITALIA DEVELOPMENT
The external genitalia arise from the genital tubercle, the urogenital groove and
sinus, and the labioscrotal fold.
As opposed to male development where testosterone plays a key role in
differentiation, estrogen is not involved in female sexual differentiation. Instead, it is
produced by the ovaries to function as support for follicular maturation. In fact, both
male and female fetuses are exposed to high amount of estrogen from their mother.
The embryo has a predisposition to develop internal female duct systems (fallopian
tubes and uterus), so unless there is an active intervention by anti-mullerian hormone
(secreted by Sertoli cells) and testosterone (secreted by the steroidogenic Leydig cells)
to promote development of the epididymis, vas deferens, efferent ducts, and other male
organs, a female system will develop. Furthermore, male external genitalia are
dependent on specific hormonal activity. The undifferentiated embryo is very rich in
androgen receptors. Once the Leydig cells start producing androgen, particularly
dihydro testosterone, the male external genitalia develop, first into a phallus, and then
further into the mature penis, phallic urethra, and scrotum. The absence of androgen
causes the development of the clitoris, urethra, vagina, and labia. This further
demonstrates that male external genitalia formation requires active intervention
(Schoenwolf et al. 2009). This is why it is said that an embryo, if left to its own
devices, will go to “default development” and develop female.
This concludes a summary of sex differentiation (Figure 4). Most discoveries of
the mechanisms involved in this development were discovered when studying patients
with an abnormal sex development or disorder of sex development.

Figure 4: Timeline of the primary and secondary sex development. Source:
http://www.embryology.ch/images/imagegraphe/u1e_schemdifferentEn.gif.

DISORDERS OF SEX DEVELOPMENT
Disorders of sex development are defined as any congenital condition in which
development of chromosomal, gonadal, or anatomical sex is atypical (The Intersex
Society of North America 2006). As seen earlier, sex differentiation is a complex and
lengthy process, involving many different genomic pathways. As a result, there are
many different variations along the developmental process which can cause atypical
presentation. If a mutation exists which impedes the development of one of the
necessary functions, it is expected that an abnormal phenotype will occur. Disorders of
sex development is a very broad term which spans a spectrum of various different
phenotypical presentations. The defining factor in determining the outcome of a
variation depends on which point of development it affects. The first step of sex
differentiation is genetic sex. Examples of disturbances in the proper genetic sex
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development are Turners Syndrome (45 XO female), Klinefelters Syndrome (47 XXY
male), XYY syndrome, and a few others. The next step in sexual determination is
gonadal sex. Disorders of gonadal sex include XX Gonadal Dysgenesis and XY
Gonadal Dysgenesis. The final part of sex development is anatomical sex. Variations in
anatomical sex are the broadest of the three steps of sex development. Conditions
range from phenotypical female, ambiguous genitalia, and phenotypical male. These
conditions include congenital adrenal hyperplasia, androgen insensitivity syndrome,
hypospadias, 5-alpha-reductase deficiencies, and many others (The Intersex Society of
North America 2006).

XY GONADAL DYSGENESIS

One of the defining moments in male or female sex differentiation is the identity
of the mature undifferentiated gonad. Once the gonad has differentiated to either testis
or ovary, it initiates steroidogenic activity which will define the rest of the anatomical
development. If gonadal development were to halt at the stage of indifference, such an
occurrence would be called XY gonadal dysgenesis. The term gonadal dysgenesis
involves the broader group of conditions that would cause the dysgenesis, or failure to
develop, of the gonads. In Turner Syndrome, gonadal development fails due to a
monosomy of the sex chromosome; the gonads are missing crucial genes for gonadal
development. In a condition known as XX gonadal dysgenesis, gonads which should
develop into ovaries are missing ovarian defining genes or receptors to complete
ovarian development. Perhaps the most fascinating is that of an XY fetus developing
phenotypically as a female due to gonadal dysgenesis in a condition called XY gonadal
dysgenesis (Sinclair and Cameron 2004).

CLINICAL PRESENTATION
XY Gonadal Dysgenesis is usually diagnosed when a patient who failed to
develop secondary female sex characteristic undergoes testing to determine the cause.
The patient usually presents a female phenotype but no or sparse pubic and underarm
hair, no or little breast tissue development, and amenorrhea. Examinations and
ultrasound images reveal usual female external genitalia, fallopian tubes, and uterus
but no visible ovaries. The incidence of occurrence is hard to estimate, with some
papers stating numbers as frequent as 1:30,000 and others quoting numbers as low as
1:150,000 (Wilhelm 2010).

TREATMENT
Although XY Gonadal Dysgenesis is not a diagnosis that comes along with
serious medical conditions (except in gene specific abnormalities that will be discussed
later), it does come along with some medical aspects that need to be addressed.
HORMONE REPLACEMENT THERAPY (HRT)
One option is to substitute the hormones that the patient is missing due to the
dysfunctional gonads. Patients with XY Gonadal Dysgenesis need to start hormone
replacement therapy to initiate pubertal development, and they need to remain on the
therapy to maintain optimal health. The doctor will usually start off the patient on a
low dosage of estrogen, most often in the form of a 0.3 mg tablet of premarin, a form of
estrogen. The dose will increase over a span of 2-3 years. The incremental increase is
intended to mimic the hormonal activity that normally would take place at the start of

76

Griendy Indig-Weingarten

puberty. During this time, all the expected secondary sex characteristic should
develop.
Because the uterus is also maturing during this time, it is important to initiate
menstruation with progesterone to reduce the risk of uterine cancer. A doctor will
usually recommend bringing on a menses a minimum of four times a year for the
upkeep of optimal uterine health. There are a number of different forms of HRT:
tablets, patches, gels, injections, and implantable pellets. Some health professionals
recommend taking a combined form of estrogen and progesterone, and some add a low
dose of testosterone to more accurately mimic the natural hormone production in
healthy females. There are conflicting reports as to what form and dose is optimal, and
most patients find that the process to find the right regimen depends on what works
best for them personally (WebMD 2009).
GONADECTOMY
Patients with XY gonadal dysgenesis must undergo a gonadectomy, surgery to
remove the streak gonads so that they do not develop into dysgerminomas (germ cell
tumors). The risk of an XY gonadal dysgenesis patient developing cancer is estimated
at around 30% occurrence rate, which is why doctors recommend that gonadectomy
be preformed soon after diagnosis. Dysgerminomas can develop in adults with streak
gonads due to their indifferent embryonic structures which are not intended to be
mature organs. The gonadal tissue of the
streak gonads contains germ cells and many
pre-Sertoli/granulose
cells
scattered
throughout the stroma. These cells can
develop into gonadoblastomas, benign
neoplasms, exclusive to these types of cells.
These neoplasms can become malignant and
form dysgerminomas and other malignant
growths (Michala et al. 2008). Cases have
been reported in which patients as young as
nine months have developed dysgerminomas
(Dumic et al. 1993); therefore doctors
recommend removing the gonads as early as Figure 5: Laparoscopic removal of streak
possible. With the advances of modern gonads (indicated by the white arrows) in
surgical techniques, most gonadectomies are patient with XY Gonadal Dysgenesis.
Source:
done laparoscopically and involve minimal http://radiographics.rsna.org/content/28/7/1891
recovery with little scarring (Figure 5).
/F14.large.jpg

GENETIC CAUSES OF XY GONADAL DYSGENESIS
Five genes have been identified in relation to XY gonadal dysgenesis. Because
of the rarity of the condition and the constantly developing field of molecular genetics,
many of their mechanisms are poorly understood.
SRY
Mutations in the SRY gene (the testis-determining gene) have been found in 1015% of all XY Gonadal Dysgenesis. Most mutations are in the HMG (High Mobility
Group) box on the SRY gene. The HMG box is capable of sequencing specific DNA
binding and bending. This is crucial in the SRY gene, because it is the specific bending
pattern which activates the SRY in the gonads. The bends act by changing the
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chromatin structure in the regulatory region of the target gene that starts the assembly
of the regulatory complex. The identification of HMG as the critical region was
formed when researchers noticed that there are variations in the non-HMG portions of
the SRY nucleotide sequences which do not have any effect on testicular development.
This finding demonstrated that these regions are not involved in testis development. As
previously mentioned, SRY is expressed in the genital ridge for a brief time, stimulating
Sertoli cell and testis determination (Sinclair and Cameron 2004). A few factors have
been identified as regulators for SRY. The WT1 may activate SRY through an SRY
promoter region which it expresses. It is also hypothesized that the SRY gene itself
might have a transcription site on it for auto regulation (Vilain et al. 1992). The roles
identified in SRY include the induction of the mesonephric cells into the ridge to form
the testis cord, proliferation of the cells, and inducement of Sertoli cell differentiation.
The lack of SRY also causes the failure of the SOX9 and any other gene relying on SRY
as its regulatory “switch.”
SRY related XY gonadal dysgenesis has been observed in familial lines, but
most cases are de novo mutations which cause the loss of binding and its subsequent
failure to initiate testis differentiation. Although SRY is expressed in somatic cells in
different areas in the body, no other effects have been observed as a result of the SRY
mutation (Simpson 2008).
DHH
DHH, the desert hedgehog gene, is located on the twelfth chromosome and is
composed of three exons. DHH expression was observed in the testis of fetal mice. In
the ovaries of fetal mice, however, little DHH expression was observed. This led to the
initial belief that DHH is involved in testis development. The product of the DHH is
found in Sertoli cells and in Schwann cells. Therefore, patients with DHH mutation
usually have polyneuropathy (many nerves acting simultaneously). Unlike SRY which
directly affects Sertoli cell development, DHH affects the development of different cells
called peritubular myoid cells, which are cells that make a thin lining around the testis
cord. Interruption of peritubular cell proliferation will cause a failure in the
development of the testis cord, which will cause a failure in gonadal development. In
fact, DHH-deficient knockout mice showed male sterility, peritubular defects, and
testis-development failure. In addition to its role in testis cord development, studies
suggest that the DHH is a regulator signal for the differentiation of Leydig cells in the
fetal testis and is also involved in upregulating the SF-1 factor (Canto et al. 2004).
Patients with DHH mutation may have complete or partial Gonadal Dysgenesis.
Partial gonadal dysgenesis usually presents itself with slightly masculinized external
genitalia and some internal male ductal development. Some development does occur, a
result of some androgen production, usually due to a mosaic presentation, meaning
that not all cells have the mutation of the DHH gene. In complete gonadal dysgenesis,
most patients posses homozygous mutations which do not allow any DHH expression
to reach the threshold for testicular development.
DHH is also expressed in Schwann cells along peripheral nerves. Therefore,
mutations in DHH can cause a condition called polyneuropathy. Polyneuropathy is a
neurological disorder which causes many nerves to malfunction simultaneously.
Impaired nerve transmission occurs due to reduced insulation of nerves by the affected
Schwann cells (Canto et al. 2004). DHH-related gonadal dysgenesis is estimated to
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account for 20% of all complete gonadal dysgenesis cases and 50% of all partial
gonadal dysgenesis cases.
NR5A1 (SF-1)
NR5A1 encodes the SF-1 (steroidogenic factor-1) and is sometimes referred to
as the SF-1 gene. It is a nuclear receptor that binds to and regulates the transcription
of many target genes involved in gonadal and adrenal development. SF-1 was first
studied in XY gonadal dysgenesis patients displaying complete adrenal failure. This
was a direct indication of the role SF-1 plays in the formation of both gonadal and
adrenal glands. These patients had homozygous mutations and did not have any SF-1
expression. In most human studies, it is rare to find a patient with complete
adrenogonadal failure due to NR5A1. Later studies dealt with patients with
heterozygous missense and frameshift mutation affecting only parts of the gene. These
patients presented little or no adrenal failure. Many of these patients displayed
androgen biosynthesis failure and impaired leydig cell development. Some even
presented testicular tissue development (Achermann et al. 2002). This highlighted the
fact that SF-1 acts within a dose-dependent function as opposed to acting as an on and
off switch.
The prevalence of NR5A1 XY gonadal dysgenesisis low.
CBX2
A fourth gene whose mutation can cause XY Gonadal Dysgenesis is the
Chromobox homolog protein 2 (CBX2). The CBX2 gene is part of
Polycomb
Recessive Group 1 on the seventeenth chromosome, which encodes polycomb group
proteins. These proteins form large protein complexes capable of chromatin
remodeling on primordial germ cells. Chromatin remodeling initiates the transition
from mitotic division early in embryogenesis to meiosis once they are in a specific
gonad. Research also indicates that the CBX2 might have a role as a promoter of the
SF-1 (Baumann and De La Fuente 2011). Knockout mice missing the CBX2 gene
expressed skeletal abnormalities and sex reversal (Lauber et al. 2009).
DMRT1/ 9P DELETION
Deletion of the tip of the 9p chromosome is associated with gonadal dysgenesis.
This association, however, was discovered quite recently, so most research is still based
on presumption. Because the deletion of the tip of 9p affects a number of
chromosomes, patients present with complex phenotypic features including ambiguous
genitalia and craniofacial abnormality. Deletion of the DMRT1 gene, located on the
ninth chromosome, has been identified as a cause of XY gonadal dysgenesis. DMRT1 is
unregulated in the genital ridge and is, therefore, linked to testis development.
Research shows that DMRT1 is critical for maintaining the activity of other male
differentiation genes like SOX9. It is a sequence-specific transcriptional regulator,
meaning that it will regulate the transcription of other genes. In this case, it is likely
that it binds to NR5A1 and promotes SF-1 production to upkeep the continued gene
expression of SOX9. Loss of the DMRT1 gene in mice, even after undergoing complete
male development, can cause reversal of the Sertoli cells into granulose cells by
promoting the production of female promoting genes. In humans, this deletion does not
result in female development as is does in mice, but it does halt male development,
causing XY gonadal dysgenesis (Matson et al. 2011).
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CONCLUSION
With the discovery of sex chromosomes in 1921, the scientific world anticipated
that the genetics of male and female differentiation would become clearer. However, it
was not until the 1990s that the SRY gene was discovered when XY females were
studied. The study of XY females also revealed other genes involved in the different
aspects of sex differentiation. The connection between DHH and the development of
the peritubular myoid cells is evident in patients with XY gonadal dysgenesis due to a
mutation of the DHH gene. NR5A1 plays a crucial role in encoding the steriodogenic
factor-1 which plays multiple roles in gonadal cord development and further
differentiation of the testis. Another gene mutation in XY gonadal dysgenesis patients,
a mutation in CBX2, provides insight into its role in regulation of primordial germ cell
development. Studying the role of DMRT1 in regulating continued male differentiation
helps scientists gain a deeper understanding of the mechanisms involved in testicular
development.
Science is constantly evolving, and research conducted on patients with XY
gonadal dysgenesis and other disorders of sex development will further the
understanding of the different components of male differentiation and development.
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